Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
|
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [31] Clinical Outcome of the Ovarian Clear Cell Carcinoma Compared to other Epithelial Ovarian Cancers when Treated with Paclitaxel and Carboplatin
    Sirichaisutdhikorn, Daranee
    Suprasert, Prapaporn
    Khunamornpong, Surapan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (06) : 1041 - 1045
  • [32] Microscopic peritoneal metastases of epithelial ovarian cancers. Clinical relevance, diagnostic and therapeutic tools
    Kerbage, Y.
    Canlorbe, G.
    Estevez, J. P.
    Grabarz, A.
    Mordon, S.
    Uzan, C.
    Collinet, P.
    Azais, H.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2018, 46 (05): : 497 - 502
  • [33] Carbonic Anhydrase (CAIX) Expression as Diagnostic Aid in Epithelial Ovarian Cancers and Its Clinical Implication
    Farooq, Taliya
    Pua, Tarah
    Han, Liying
    Zhong, Minghao
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146
  • [34] Combination of Metformin and Chemotherapy Decreases the Recurrence Rates of Epithelial Ovarian Cancers: A Randomized Clinical Trial
    Hamedi, Bahareh
    Khalili, Azadeh
    Roozmeh, Shohreh
    Namazi, Golnaz
    Saraf, Zahra
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (07)
  • [35] DNA repair genetic profiling in epithelial ovarian cancer: An opportunity for clinical improvement?
    Assis, J.
    Coelho, S.
    Nogueira, A.
    Pinto, R.
    Brandao, M.
    Dias, J.
    Alves, S. G. C. M.
    Pereira, D.
    Medeiros, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Impact of Universal Screening Recommendation on Genetic Testing in Patients with Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers
    Gotimer, K.
    Griffiths, C.
    Jimenez, E.
    Musa, F.
    Villella, J.
    Levine, K.
    Chan, K.
    Chalas, E.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 223 - 223
  • [37] THE REVIEW OF CLEAR CELL TYPE OF EPITHELIAL OVARIAN CANCERS
    Terek, Cosan
    Dikmen, Yilmaz
    Turan, Volkan
    Ozsaran, Aydin
    Zekioglu, Osman
    Ozdemir, Necmettin
    TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 9 (03) : 129 - 132
  • [38] BRCA mutation in high grade epithelial ovarian cancers
    Manchana, Tarinee
    Phoolcharoen, Natacha
    Tantbirojn, Patou
    GYNECOLOGIC ONCOLOGY REPORTS, 2019, 29 : 102 - 105
  • [39] The spread pattern of right and left epithelial ovarian cancers
    Ayhan, A.
    Yuksel, H.
    Dursun, P.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (06) : 654 - 657
  • [40] THE PROGNOSTIC VALUE OF MORPHOMETRY IN ADVANCED EPITHELIAL OVARIAN CANCERS
    KATSOULIS, M
    LEKKA, J
    VLACHONIKOLIS, I
    DELIDES, GS
    BRITISH JOURNAL OF CANCER, 1995, 72 (04) : 958 - 963